According to an analysis conducted by BioWorld of the third-quarter 2019 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) in the period increased almost 70% compared to the same period in 2018. Read More

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018. Read More

The FDA has typically used real-world evidence (RWE) as a way of monitoring safety issues post-approval, especially through the Sentinel Initiative, which started in response to the FDA Amendments Act of 2007. Read More

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Affimed NV priced its public offering for net proceeds expected to be approximately $28.2 million. Read More

“We’re surprised by this outright failure as well as the lack of an investor call to discuss the most significant development in the history of the company.” Read More

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously concluded that Amarin Corp. plc provided sufficient evidence of efficacy and safety to support approval of fish oil-based Vascepa (icosapent ethyl). Read More

Regulatory decisions affecting biopharma products in development, including approvals, recommendations, rejections and the granting of regulatory pathways in October 2019. Read More

The top 10 biopharma stock gainers and losers for the week of Nov. 11-15, 2019. Read More

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes. Read More